The goal of this study is to compare plasma biomarkers in the form of extracellular RNA in dogs with mitral valve disease presenting with versus without congestive heart failure.
This study will be an important step towards making exosome analysis a useful and readily available tool for evaluating the progression, the molecular basis for remodeling, and development of specific therapies for mitral valve disease.
All dogs should be over eight years of age in order to control for age-related differences.
Healthy: for controls the dogs will be defined as a healthy animal with a normal physical exam, normal CBC/chemistry panel/UA and no evidence of a heart murmur as documented by a veterinarian
There will be four populations that will be included in this study:
Group 1: Healthy dogs with no cardiac disease
Group 2: Dogs with mitral valve disease not in congestive heart failure.
Group 3: Dogs with mitral valve disease in congestive heart failure.
For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: email@example.com
Is Your Pet Eligible?
If you believe that your pet may be eligible for this study, please complete our prescreening questionnaire for owners.
If you believe you have a patient who is eligible for this clinical trial study or you would like additional information from the Clinical Trials Office at the Cummings Veterinary Medical Center, complete a referring physician questionnaire.